Fv antibody fragments have been used as co-crystallization partners in structural biology, particularly in membrane protein crystallography. However, there are inherent technical issues associated with the largescale production of soluble, functional Fv fragments through conventional methods in various expression systems. To circumvent these problems, we developed a new method, in which a single synthetic polyprotein consisting of a variable light (VL) domain, an intervening removable affinity tag (iRAT), and a variable heavy (VH) domain is expressed by a Gram-positive bacterial secretion system. This method ensures stoichiometric expression of VL and VH from the monocistronic construct followed by proper folding and assembly of the two variable domains. The iRAT segment can be removed by a site-specific protease during the purification process to yield tag-free Fv fragments suitable for crystallization trials. In vitro refolding step is not required to obtain correctly folded Fv fragments. As a proof of concept, we tested the iRAT-based production of multiple Fv fragments, including a crystallization chaperone for a mammalian membrane protein as well as FDA-approved therapeutic antibodies. The resulting Fv fragments were functionally active and crystallized in complex with the target proteins. The iRAT system is a reliable, rapid and broadly applicable means of producing milligram quantities of Fv fragments for structural and biochemical studies.
Introduction
Structural studies of key proteins that are involved in biologically and medically relevant molecular processes are frequently abandoned because of difficulties in preparing diffraction-quality crystals. In most cases, their molecular flexibility, conformational heterogeneity or polydispersal characteristics in solution hinders protein crystallization. Chaperone-assisted crystallography is a powerful strategy to address this problem and can be applied to a broad range of membrane proteins and otherwise 'uncrystallizable' soluble proteins, such as heavily glycosylated and multi-domain proteins 1, 2 . The chaperone molecules aid in crystallization by increasing the hydrophilic surface area available for rigid crystal lattice formation. The bound chaperone molecules reduce the inherent protein flexibility and conformational heterogeneity, thereby increasing the chance of successful crystallization of difficult target proteins. Different protein scaffolds have been used as crystallization chaperones, ranging from animal-derived antibody fragments 3, 4 to synthetic binders such as DARPins 5 and Monobodies 6 . DNA and RNA aptamers have also been applied as co-crystallization partners 7, 8 . Among the reported chaperones, Fv antibody fragment is a promising scaffold that has been used to crystallize of a variety of membrane proteins including bacterial cytochrome c oxidase 9,10 , yeast cytochrome bc1 complex 11 , archaeal KvAP voltage-gated potassium channel 12 , human adiponectin receptors 13 and the mammalian fructose transporter GLUT5 14 . In addition, the compactness of Fv fragments affords additional advantages in structural studies examining the antigen-antibody interface, such as the characterization of therapeutic antibody blocking mechanisms 15, 16 .
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Preparation of milligram quantities of purified Fv fragments is the most critical prerequisite when Fv fragments are used as co-crystallization partners.
Several studies evaluating the quantity and quality of Fv fragments produced from different expression systems have been performed. Bicistronic VL-VH overexpression in the Escherichia coli periplasm results in relatively low yields (0.5-1 mg per liter of culture) 17 . Recovery of functional Fv fragments from E. coli cytoplasmic inclusion bodies requires a laborious and time-consuming refolding process during purification 18 . In contrast, Gram-positive bacteria lack an outer membrane and have a powerful secretion apparatus that allows disulfide bond formation and the proper folding of antibody fragments in an oxidizing environment. Bicistronic VL-VH secretory expression has been tested in Streptomyces lividans to purify a certain Fv fragment 19 , but it is not known whether this method can be practically applied to a wide range of antibody clones. Production of Fv fragments by two-membered culture of the separate VLand VH-expression strains in Brevibacillus chosinensis secretory system 14 is problematic when either strain proliferates too rapidly.
To solve these problems, we have developed a new expression strategy in which the stoichiometric secretion and assembly of the VL and VH domains are achieved by monocistronic expression in the Gram-positive bacterium B. choshinensis. A polyhistidine-maltose binding protein (His6-MBP) cassette, embedded within the intervening region of the two variable domains, serves as an affinity purification tag that can be removed by tobacco etch virus (TEV) protease cleavage. We chose the name "iRAT (intervening removable affinity tag) system" to describe this production strategy. Here, we present a reliable and broadly applicable method for preparing milligram quantities of Fv fragments.
This method was validated through the production of multiple Fv fragments derived from murine and humanized monoclonal antibodies including therapeutic antibodies approved by the U.S. Food and Drug Administration (FDA). The suitability of the resulting Fv fragments for structural studies was also demonstrated through co-crystallization and X-ray diffraction analyses.
Results

Concept and development of the iRAT system
We developed the iRAT system to address the need for a reliable method to control the 1:1 stoichiometric expression and the proper folding of the VL and VH domains, each of which contains an intrachain disulfide bond. To increase the throughput of crystallization trials, it is ideal to collect soluble and functional Fv fragments with high yields by using simple purification procedures without in vitro refolding, a time and labor intensive process. Considering these prerequisites, we generated a synthetic polyprotein encoding both the VL and VH domains by using a monocistronic expression strategy in a Gram-positive bacterial secretion system. Specifically, the new expression vector pBIM2 contained the VL-and VH-coding sequences cloned in a single reading frame (Fig.   1A ). The two variable domains were tethered together by the iRAT segment, which contained the first TEV cleavage site, the His6 tag, a linker, MBP, another linker and the second TEV cleavage site in that order. The iRAT portion can be removed by cleavage with His6-tagged TEV protease (TEV-His6) followed by reverse immobilized metal-affinity chromatography (IMAC) ( Fig. 1B and Methods). MBP was included to enhance the secretory expression of the synthetic polyprotein. The purification yields for iRAT-based Fv expression were 1.5 to 1.7-fold higher than those of the non-MBP fusion. Another reason for including MBP is that the distance between the N-and C-termini (43 Å) is similar to the distance between the C-terminus of VL and the N-terminus of VH (approximately 35-40 Å) for most Fv fragments 20 . The construct was cloned downstream of the constitutively active promoter P5 and the Sec signal peptide for polyprotein secretion into the culture supernatant.
iRAT-based production of a crystallization chaperone for the rat fructose transporter GLUT5
In a previous study, an Fv fragment (clone number: 4D111) was used to improve the crystallization of the rat GLUT5 fructose transporter 14 . We tested the largescale expression and purification of the Fv 4D111 by using the iRAT system.
Brevibacillus cells harboring the pBIM2-based construct were cultivated for 48 h.
Afterward, Fv 4D111 was purified from the culture supernatant by using ammonium sulfate precipitation followed by IMAC, TEV cleavage, reverse IMAC and size exclusion chromatography (SEC) (Methods). The yield of purified Fv 4D111 was 4.1 mg per liter of culture, and no apparent aggregation occurred when the purified protein was concentrated to ~10 mg/mL. A typical SEC elution profile for Fv 4D111 is shown in Figure 2A . The elution peak was monodisperse, and oligomer formation was not observed. Calibration with molecular standards revealed that the Fv 4D111 existed as a monomer in solution with an apparent molecular weight of ~26 kDa. SDS-PAGE under reducing conditions showed a double band with the expected mobility of the VL and VH domains ( Fig. 2B ).
To test whether the purified Fv fragment was functional, SEC of the rat GLUT5 transporter in complex with Fv 4D111 was performed. A molar excess of Fv 4D111 was mixed with GLUT5 and loaded onto an SEC column. Complex formation was indicated by an elution peak shift toward higher molecular weights, as compared with uncomplexed GLUT5 (Fig. 2C ). SDS-PAGE analysis of the high molecular weight peak clearly showed the presence of both GLUT5 and Fv 4D111 ( Fig. 2D ). Surface plasmon resonance (SPR) experiments indicated that iRAT-produced Fv 4D111 bound GLUT5 with a KD value of 2.4 nM ( Fig. 2E ). The thermal stability of GLUT5 in the presence or absence of Fv 4D111 indicated that this antibody fragment increased the Tm by 12.5°C after GLUT5 binding, thus suggesting that Fv 4D111-bound GLUT5 was significantly stabilized (Fig. 2F ).
Furthermore, the GLUT5-Fv 4D111 complex was able to be crystallized ( Fig. 2G , inset). The co-crystals diffracted up to 3.2 Å and generated complete diffraction sets, which were able to be processed to solve the structure of the GLUT5-Fv complex ( Fig. 2G ). These results suggest that the iRAT system is useful for the production of Fv scaffold-based crystallization chaperones in milligram quantities.
iRAT-based production of Fv fragments of therapeutic antibodies for cocrystallization with their targets
A structure-based understanding of the interactions between therapeutic antibodies and target proteins is critical to the rational design of improved biotherapeutics. However, a relatively small number of crystal structures have been determined for therapeutic antibody-target protein complexes, which probably reflects the lack of simple methods facilitating production of recombinant antibody fragments in milligram quantities, resulting in limited success in co-crystallization trials. Typical examples include certolizumab and denosumab. Certolizumab is a humanized monoclonal antibody that targets the tumor necrosis factor α (TNFα) and is used to treat rheumatoid arthritis and Crohn's disease 21 . Denosumab is a human monoclonal antibody that targets the receptor activator of nuclear factor κB ligand (RANKL) and is used to treat osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumors of the bone 22 . Although the U.S. FDA has approved these two antibodies, the interactions between the antibodies and their target molecules have not been accurately mapped at atomic-level resolution by crystallographic analyses. To demonstrate the utility of the iRAT system, we produced Fv fragments derived from these two therapeutic antibodies.
Amino acid sequence data for the antibodies were retrieved from DrugBank (http://www.drugbank.ca/). Codon-optimized cDNAs encoding the VL and VH domains were artificially synthesized and cloned into the pBIM2 vector.
The certolizumab Fv and the denosumab Fv were readily expressed and purified to greater than 95% purity with yields of 15. Fab fragments. Single-chain Fv (scFv) fragments are similar to Fv fragments, but the linker between the VL and VH domains makes scFv fragments prone to forming intermolecularly domain-swapped dimers 23 . The dimer-monomer equilibrium of scFv fragments can increase structural heterogeneity; therefore, an antibody in scFv format is less desirable for crystallization. In addition, Fv fragments are less prone to distortion than scFv fragments because aggregation of scFv fragments is sensitive to the linker length. Nanobodies (VHHs) are increasingly finding favor with crystallographers due to their small size, ease of expression and purification, and extreme structural stability. Another fascinating feature of Nanobodies is their extended convex paratope structure that can bind deep into molecular clefts to trap the target in a particular conformational state 4 .
However, Fv fragments have an advantage over Nanobodies in more efficient enlargement of hydrophilic surfaces for crystal contacts because of the larger molecular size.
Fv fragments are heterodimeric molecules consisting of two domains, VL and VH, that assemble through hydrophobic interactions. Each of the VL and VH domains contains an intrachain disulfide bond for stabilization. These structural properties require a sophisticated apparatus for secretion, folding, and assembly as well as an oxidizing environment for disulfide bond generation. B. choshinensis is well known for its capacity to secrete large amounts of proteins directly into the culture medium. Expression of Fv fragments via the B. choshinensis Secdependent secretion pathway ensures the formation of the intrachain disulfide bonds to stabilize the structure. Thus, we combined the advantages of monocistronic stoichiometric expression with those of Gram-positive bacterial secretory expression to develop the iRAT system. To make this system suitable for structural studies, the linker segment that tethers the VL and VH domains can be cleaved by the site-specific protease and removed during the purification process.
The iRAT system is a streamlined pipeline that provides the desired intermediate throughput to produce many Fv fragments in parallel. The typical duration for running one cycle of the iRAT-production procedure, from plasmid construction to protein purification, is 10 days. The procedure is easy and costeffective and does not require any time-consuming or labor-intensive steps. The iRAT system generally produces high Fv fragment purification yields sufficient for structural studies. We have tested the iRAT-based expression and purification of randomly chosen 17 different Fv fragments and found that the yields exceed 3 mg per liter of culture in 12 out of them (data not shown). These yields considerably exceed those obtained from equivalent constructs expressed in the E. coli periplasm. A limitation of the iRAT system is the yield variability among individual antibody clones, which can be attributed to the sequence of the variable domains and the stability of the hydrophobic interactions between them.
However, we have not identified specific sequence motifs and other factors that affect the yields; hence the yield cannot be judged in advance on the basis of the sequence information alone.
Overall, the iRAT production system is an accessible method for use in a broad range of Fv antibody-mediated crystallography and structure-based research on the binding modes of therapeutic antibodies. Moreover, it may generally be applicable to the large-scale production of antibody reagents and therapeutics.
Methods
Plasmid construction
The pBIM2 vector (Fig. 1A) 
E. coli TOP10 cells harboring the expression plasmid for human RANKL
were grown overnight at 37°C and 250 rpm in LB supplemented with 100 mg/L ampicillin. The culture was diluted 1:100 into 200 mL of the same medium and grown at 37°C to an OD600 of 0.5 followed by overnight incubation at 20°C with 0.02% arabinose. The cells were harvested by centrifugation at 6,000 g for 15
min and re-suspended in buffer S1 (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 20 mM imidazole, 0.1% Triton X-100, Roche EDTA-free protease inhibitor tablet).
Cells were disrupted by sonication followed by DNaseI treatment on ice for 30 min. The lysate was clarified via centrifugation and loaded onto a HisTrap Crude column (GE Healthcare) equilibrated with buffer A. Bound proteins were eluted with buffer B, mixed with TEV-His6 and dialyzed overnight against TBS buffer.
The cleaved NusA-His6 tag and TEV-His6 were removed using a HisTrap HP column equilibrated with buffer A. The flow-through fractions were concentrated and loaded onto a Superdex200 10/300GL column (GE Healthcare) equilibrated with TBS buffer. The peak fractions were pooled, concentrated, flash frozen in liquid nitrogen, and stored at -80°C.
Rat GLUT5 was expressed and purified using previously described methods 14 .
SPR experiments
SPR experiments were performed at 20°C using a Biacore T100 with series S streptavidin sensor chips (Series S sensor chip SA; GE Healthcare) in TBS 
Thermal stability assay
The thermal stability of GLUT5 was evaluated in the presence or absence of Fv 
Diffraction data collection and analysis
The diffraction data were collected at 100 K at the SPring-8 beamline BL41XU
(Japan) using a MX225HE (Rayonix) or PILATUS3 6M (Dectris) detector. The data were then integrated and scaled using HKL2000 25 or XDS 26 
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